Researchers examined data from the Veterans Affairs Central Cancer Registry and found that men with prostate cancer who received androgen blockade therapy had an 18% lower risk of developing a secondary lung cancer than those who didn't get such treatment. The findings were presented at the annual meeting of the American Association for Cancer Research.

Related Summaries